Tumor pO2 as a surrogate marker to identify therapeutic window during metronomic chemotherapy of 9L gliomas

Advances in Experimental Medicine and Biology

Volumn 701, Issue , 2011, Pages 107-113

  Mupparaju, Sriram ^a,b   Hou, Huagang ^a   Lariviere, Jean P ^a   Swartz, Harold M ^a   Khan, Nadeem ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CANCER GROWTH; CLINICAL PROTOCOL; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFECT; ELECTRON SPIN RESONANCE; GLIOBLASTOMA; HYPOXEMIA; IN VIVO STUDY; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; OXIMETRY; OXYGEN TENSION; PRESSURE MEASUREMENT; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; TISSUE OXYGENATION; TUMOR VASCULARIZATION; TUMOR VOLUME;

EID: 84934439127     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-7756-4_15     Document Type: Conference Paper

References (13)

1. Buckner JC. Factors influencing survival in high-grade gliomas. Semin Oncol 30:10-14, 2003. (Pubitemid 38199157)
2. Buckner JC, Brown PD, O'Neill BP,Meyer FB,Wetmore CJ, Uhm JH. (2007) Central nervous system tumors. Mayo Clin Proc 82:1271-1286. (Pubitemid 47502884)
3. DeAngelis LM. (2001) Brain tumors. N Engl J Med 344:114-123. (Pubitemid 32052502)
4. Fukumura D, Jain RK. (2007)Tumor microvasculature and microenvironment: Targets for antiangiogenesis and normalization. Microvasc Res 74:72-84. (Pubitemid 350051025)
5. Hou H, Khan N, Grinberg OY, Yu H, Grinberg SA, Lu S, Demidenko E, Steffen RP, Swartz HM. (2007)The effects of Efaproxyn (efaproxiral) on subcutaneous RIF-1 tumor oxygenation and enhancement of radiotherapy-mediated inhibition of tumor growth in mice. Radiat Res 168:218-225. (Pubitemid 351295151)
6. Hou H, Lariviere JP, Demidenko E, Gladstone D, Swartz H, Khan N. (2009) Repeated tumor pO(2) measurements by multi-site EPR oximetry as a prognostic marker for enhanced therapeutic efficacy of fractionated radiotherapy. Radiother Oncol 91:126-131.
7. Jain RK. (2005) Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307:58-62. (Pubitemid 40093472)
8. Khan N, Williams B, Swartz H. (2006) Clinical applications of in vivo EPR: Rationale and initial results. Applied Magn Reson 30:185-199,. (Pubitemid 44432675)
9. Khan N,Williams BB, Hou H, Li H, Swartz HM. (2007)Repetitive tissue pO2 measurements by electron paramagnetic resonance oximetry: Current status and future potential for experimental and clinical studies. Antioxid Redox Signal 9:1169-1182. (Pubitemid 47080827)
10. Kim JT, Kim JS, Ko KW, Kong DS, Kang CM, Kim MH, Son MJ, Song HS, Shin HJ, Lee DS, Eoh W, Nam DH. (2006) Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. Oncol Rep 16:33-39.
11. Ma J,Waxman DJ (2007).Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment. Mol Cancer Ther 6:2879-2890. (Pubitemid 350206766)
12. Swartz HM, Clarkson RB. (1998) The measurement of oxygen in vivo using EPR techniques. Phys Med Biol 43:1957-1975. (Pubitemid 28335419)
13. Zhou Q, Guo P, Wang X, Nuthalapati S, Gallo JM. (2007) Preclinical pharmacokinetic and pharmacodynamic evaluation ofmetronomic and conventional temozolomide dosing regimens. J Pharmacol Exp Ther 321:265-275. (Pubitemid 46456967)